Description
Duotir (Tirzepatide) is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist a subcutaneously injected, synthetic incretin-based peptide that simultaneously activates both the GIP receptor and the GLP-1 receptor to deliver complementary and synergistic mechanisms of glucose-lowering, insulin sensitisation, and body weight reduction not achievable with selective GLP-1 receptor agonism alone supplied as a single-dose pre-filled syringe in three strengths: 2.5 mg/0.5 mL, 5 mg/0.5 mL, and 7.5 mg/0.5 mL and manufactured by Opsonin Pharma Ltd. in Bangladesh. Its active ingredient, tirzepatide INN, is a 39-amino acid acylated peptide engineered on a GIP receptor agonist scaffold that incorporates GLP-1 receptor binding activity, enabling dual receptor co-agonism with a pharmacokinetic half-life of approximately 5 days that supports once-weekly subcutaneous administration.
Dual GIP/GLP-1 receptor activation by tirzepatide stimulates glucose-dependent insulin secretion from pancreatic beta cells, suppresses postprandial glucagon secretion from pancreatic alpha cells, slows gastric emptying to reduce postprandial glucose excursions, reduces hepatic glucose production, improves peripheral insulin sensitivity through GIP receptor-mediated adipose tissue glucose uptake, and reduces energy intake and body weight through central appetite-suppressing mechanisms acting on GLP-1 receptors in the hypothalamus and brainstem.
In the pivotal Phase 3 SURPASS-1 trial, tirzepatide 5 mg once weekly achieved a mean HbA1c reduction of 1.87% from baseline versus 0.04% with placebo at 40 weeks (p<0.001), with 87% of patients achieving HbA1c below 7.0% versus 20% with placebo (p<0.001). In the head-to-head Phase 3 SURPASS-2 trial against semaglutide 1 mg once weekly, tirzepatide 5 mg once weekly achieved mean HbA1c reduction of 2.01% versus 1.86% with semaglutide 1 mg (p<0.001 for superiority), establishing the first once-weekly dual GIP/GLP-1 receptor agonist to demonstrate superiority over semaglutide in HbA1c reduction and body weight loss in adults with type 2 diabetes. Searching for Duotir Tirzepatide? Mediaid Pharmacy lists this product across its diabetes medicines and Opsonin Pharma portfolios and ships it worldwide.
Basic Product Information of Duotir (Tirzepatide)
| Brand Name | Duotir (Tirzepatide) |
| Product Name | Duotir |
| Generic Name | Tirzepatide INN |
| Drug Class | First-in-Class Dual GIP and GLP-1 Receptor Agonist (Twincretin); Incretin Mimetic; Glucose-Dependent Insulinotropic Polypeptide (GIP) Receptor Agonist; Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist; Antidiabetic Agent; Anti-Obesity Agent; Subcutaneous Peptide; Pancreatic Beta Cell Stimulant; Glucagon Suppressor; Gastric Emptying Modulator |
| Formulation | Subcutaneous Injection (Single-Dose Pre-Filled Syringe) |
| Available Strengths | 2.5 mg/0.5 mL, 5 mg/0.5 mL, and 7.5 mg/0.5 mL tirzepatide per pre-filled syringe |
| Available Pack Size | Single-dose pre-filled syringe per box (one injection per box) |
| Dosing & Dose Escalation | Starting dose: 2.5 mg subcutaneously once weekly for the first 4 weeks (initiation dose only not intended as a glycaemic control maintenance dose). Escalation to 5 mg: After 4 weeks on 2.5 mg, increase to 5 mg once weekly. The 5 mg dose may be used as a maintenance dose if glycaemic targets are met and tolerated. Escalation to 7.5 mg: If additional glycaemic control is required after at least 4 weeks on 5 mg and the dose is tolerated, increase to 7.5 mg once weekly. Administration: Inject subcutaneously once weekly in the abdomen, thigh, or upper arm. The day of the week may be changed if the time between doses is at least 3 days (72 hours). Administer Duotir on the same day each week for consistent pharmacodynamic coverage. If a dose is missed and the next scheduled dose is more than 4 days away, administer as soon as possible; if the next scheduled dose is within 4 days, skip the missed dose and resume on the regular schedule. Do not administer intravenously or intramuscularly. Do not mix Duotir with other injectable medicines in the same syringe. Do not share pre-filled syringes between patients even if the needle is changed. |
| Primary Indications | Type 2 Diabetes Mellitus: As an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus. Chronic Weight Management: As an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with initial body mass index (BMI) of 30 kg/m² or greater (obesity), or 27 kg/m² or greater (overweight) with at least one weight-related comorbidity. Each treatment decision must account for baseline HbA1c, renal function, cardiovascular risk, personal or family history of medullary thyroid carcinoma (MTC), pancreatitis history, and concomitant antidiabetic medications always consult the full prescribing information and the treating endocrinologist or diabetologist. |
| Manufacturer | Opsonin Pharma Ltd., Bangladesh |
| Country of Origin | Bangladesh |
| Originator Reference Brand | MOUNJARO® (tirzepatide injection, by Eli Lilly approved by the FDA in May 2022 for type 2 diabetes mellitus in adults as an adjunct to diet and exercise) and ZEPBOUND® (tirzepatide injection, by Eli Lilly approved by the FDA in November 2023 for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity). Both MOUNJARO® and ZEPBOUND® contain tirzepatide INN as the active pharmaceutical ingredient in the same first-in-class dual GIP/GLP-1 receptor agonist drug class. Duotir is manufactured by Opsonin Pharma Ltd. in Bangladesh and is supplied through Mediaid Pharmacy for international procurement. |
| Global Supplier | Mediaid Pharmacy, Worldwide Shipping Available |
| Storage Conditions | Store refrigerated at 2°C to 8°C (36°F to 46°F). May be stored at room temperature up to 30°C (86°F) for a single period of up to 21 days if needed. Do not freeze; discard if the product has been frozen. Keep the pre-filled syringe in its original carton and protect from light. Keep out of the reach of children. Do not use if the solution is discoloured, cloudy, or contains particles. |
How Duotir (Tirzepatide) Works: First-in-Class Dual GIP and GLP-1 Receptor Agonism in Type 2 Diabetes and Obesity
Tirzepatide INN is the world’s first approved dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor two G protein-coupled receptors (GPCRs) expressed on pancreatic beta cells, adipose tissue, brain, liver, stomach, and cardiovascular tissue that represent two of the three principal incretin hormone axes governing postprandial glucose homeostasis, insulin sensitivity, and energy balance. GIP is secreted by K cells in the duodenum and proximal jejunum in response to fat and carbohydrate ingestion, potentiating glucose-dependent insulin secretion from pancreatic beta cells and directly stimulating glucose uptake into adipose tissue, skeletal muscle, and the liver.
GLP-1 is secreted by L cells in the distal ileum and colon in response to luminal nutrients, potentiating glucose-dependent insulin secretion, suppressing glucagon secretion from pancreatic alpha cells, slowing gastric emptying, and activating GLP-1 receptors in the hypothalamus and area postrema of the brainstem to reduce appetite, increase satiety, and decrease food intake. In type 2 diabetes, both GIP receptor responsiveness and GLP-1 secretory response are impaired by chronic hyperglycaemia and insulin resistance producing the blunted incretin effect that accounts for approximately 50% of the lost postprandial insulin response in established type 2 diabetes.
Tirzepatide is a synthetic 39-amino acid acylated peptide engineered on a GIP receptor agonist backbone with embedded GLP-1 receptor binding activity, acylated with a C20 fatty diacid moiety via a gamma-glutamic acid linker to an internal lysine residue enabling albumin binding that extends the plasma half-life to approximately 5 days and supports once-weekly subcutaneous administration. Following subcutaneous injection of Duotir (Tirzepatide), tirzepatide binds the GIP receptor and GLP-1 receptor simultaneously, activating adenylyl cyclase and elevating cyclic AMP in both receptor-expressing cell types, stimulating PKA and EPAC2 signalling to augment glucose-dependent insulin exocytosis from pancreatic beta cells, suppress glucagon from alpha cells, decelerate gastric emptying to attenuate postprandial glucose spikes, improve hepatic insulin sensitivity, increase peripheral glucose disposal, and activate central satiety pathways to reduce energy intake and body weight.
The clinical consequence of dual GIP and GLP-1 receptor agonism in type 2 diabetes is greater HbA1c reduction and body weight loss than observed with selective GLP-1 receptor agonists, including semaglutide 1 mg the GLP-1 receptor agonist that set the prior efficacy benchmark in the drug class. In the SURPASS-2 trial (1,879 patients), tirzepatide 5 mg once weekly reduced HbA1c by 2.01% versus 1.86% with semaglutide 1 mg at 40 weeks (p<0.001 for superiority), and tirzepatide reduced body weight by 7.6 kg (5 mg) versus 5.3 kg with semaglutide 1 mg with tirzepatide 5 mg achieving HbA1c below 7.0% in 82% of patients versus 79% with semaglutide 1 mg. In SURMOUNT-1 (2,539 patients with obesity but without type 2 diabetes), tirzepatide 5 mg once weekly achieved mean body weight reduction of 15.0% versus 2.4% with placebo at 72 weeks, and tirzepatide 10 mg achieved 19.5% and tirzepatide 15 mg achieved 22.5% body weight reduction versus 2.4% placebo (p<0.001 for all doses).
The key pharmacological advantage of tirzepatide’s dual GIP/GLP-1 mechanism versus selective GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) is additive and potentially synergistic incretin receptor co-activation: GIP receptor agonism augments insulin secretion through a cAMP pathway that is partially distinct from the GLP-1 receptor cAMP pathway, and GIP receptor activation in adipose tissue promotes fat uptake and oxidation independently of GLP-1 receptor signalling producing a combined metabolic response in body weight, HbA1c, fasting glucose, postprandial glucose, and lipid parameters that exceeds what GLP-1 receptor agonism alone achieves.
Pharmacokinetically, tirzepatide reaches peak plasma concentration (Tmax) approximately 8 to 72 hours after subcutaneous injection, with an apparent half-life of approximately 5 days supporting once-weekly dosing. Tirzepatide undergoes proteolytic degradation by DPP-IV cleavage, amide hydrolysis, and beta-oxidation of the fatty acid chain. For the complete range of diabetes medicines at Mediaid Pharmacy, browse the full portfolio for worldwide shipping.
Duotir (Tirzepatide): Indications, Dosing, and Key Safety Information
| Approved Indications | Type 2 Diabetes Mellitus: Adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus. Duotir (Tirzepatide) is not indicated for the treatment of type 1 diabetes mellitus.
Chronic Weight Management: Adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial BMI of 30 kg/m² or greater (obesity class I, II, or III), or 27 kg/m² or greater (overweight) with at least one weight-related comorbidity such as hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease. |
| Recommended Dose and Titration | Initiation: 2.5 mg subcutaneously once weekly for 4 weeks (initiation and tolerability dose not intended for glycaemic or weight management as a maintenance dose). Step 1 Maintenance: Increase to 5 mg once weekly after 4 weeks on 2.5 mg. The 5 mg dose may be maintained if targets are achieved and the dose is well tolerated. Step 2 Escalation: If additional efficacy is needed after a minimum of 4 weeks on 5 mg, increase to 7.5 mg once weekly. Administer Duotir subcutaneously once weekly in the abdomen, thigh, or upper arm. Rotate injection sites weekly. The day of the week may be changed if the interval between doses is at least 3 days (72 hours). |
| Dose Modification | No dose adjustment of Duotir (Tirzepatide) is required for mild, moderate, or severe renal impairment, or for mild or moderate hepatic impairment (Child-Pugh A or B) based on available pharmacokinetic data. However, acute kidney injury has been reported in association with dehydration secondary to tirzepatide-induced gastrointestinal adverse effects ensure adequate hydration during dose escalation and in patients with renal impairment. If gastrointestinal adverse effects (nausea, vomiting, diarrhoea) are severe or persistent during dose escalation, consider delaying the dose escalation step for 4 additional weeks at the current dose before attempting re-escalation. When Duotir is used concomitantly with insulin secretagogues (sulfonylureas, meglitinides) or basal insulin, consider reducing the secretagogue or insulin dose to reduce the risk of hypoglycaemia. |
| Missed Dose | If a dose of Duotir is missed, administer it as soon as possible if there are more than 4 days (96 hours) remaining before the next scheduled weekly dose. If fewer than 4 days remain before the next scheduled dose, skip the missed dose and resume on the regularly scheduled day. Do not administer two doses of Duotir within 3 days of each other. |
| Important Warnings and Precautions | Thyroid C-Cell Tumors (Boxed Warning): Tirzepatide causes thyroid C-cell tumors in rodents at clinically relevant exposures. It is unknown whether tirzepatide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. Duotir is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Counsel patients to report any signs or symptoms of thyroid tumors (neck mass, dysphagia, dyspnoea, persistent hoarseness) to their treating physician.
Pancreatitis: Acute pancreatitis, including fatal and non-fatal cases, has been reported with GLP-1 receptor agonists. Discontinue Duotir promptly if pancreatitis is suspected. Do not restart Duotir following confirmed pancreatitis. Evaluate patients with persistent severe abdominal pain for pancreatitis, which may radiate to the back and may or may not be accompanied by vomiting. Hypoglycaemia: Duotir may increase the risk of hypoglycaemia when used in combination with insulin secretagogues (sulfonylureas) or basal insulin. Inform patients of the signs and symptoms of hypoglycaemia and instruct them to monitor blood glucose as directed. Consider reducing the dose of concomitant insulin secretagogues or basal insulin when initiating Duotir. Acute Kidney Injury: Acute kidney injury has been reported with GIP/GLP-1 receptor agonists and may be related to dehydration secondary to gastrointestinal adverse effects. Monitor renal function during dose escalation in patients with renal impairment and ensure adequate hydration. Diabetic Retinopathy Complications: Rapid improvement in glycaemic control has been associated with worsening of diabetic retinopathy. Monitor patients with a history of diabetic retinopathy. Hypersensitivity: Serious hypersensitivity reactions (anaphylaxis, angioedema) have been reported. Discontinue Duotir immediately if hypersensitivity reactions occur. Contraindications: Personal or family history of MTC; MEN2; known serious hypersensitivity to tirzepatide or any excipient of Duotir. Consult the current full prescribing information for the complete updated safety profile. |
| Common Adverse Reactions | Nausea, diarrhoea, decreased appetite, vomiting, constipation, dyspepsia, abdominal pain, and injection site reactions (erythema, pain, bruising). Gastrointestinal adverse reactions were most frequently reported during dose escalation and were generally transient and mild-to-moderate in severity. In SURPASS-2 (1,879 patients), nausea was reported in 17% (tirzepatide 5 mg) versus 18% (semaglutide 1 mg) and diarrhoea in 13% versus 12%. Adverse events leading to treatment discontinuation were 4.3% (tirzepatide 5 mg) versus 2.6% (semaglutide 1 mg). Always counsel patients regarding gastrointestinal effects, hydration during initiation and dose escalation, and the importance of reporting persistent abdominal pain or signs of hypoglycaemia to their treating endocrinologist or diabetologist. |
| Drug Interactions | Oral medications: Tirzepatide slows gastric emptying and may affect the rate of absorption of concomitantly administered oral medications. Use caution when administering oral medications that have a narrow therapeutic index or require careful monitoring of drug levels (e.g., warfarin, thyroid replacement hormones, certain anticonvulsants, digoxin) alongside Duotir. Oral contraceptives: Tirzepatide may transiently reduce the rate of absorption of oral contraceptives during the first 4 weeks following Duotir initiation or dose escalation patients should be advised to use a backup or alternative contraception method during this window. Insulin secretagogues and basal insulin: Concomitant use increases hypoglycaemia risk consider dose reduction of the sulfonylurea, meglitinide, or basal insulin. Other antidiabetic agents: No dose adjustment of Duotir is required based on co-administration with metformin, SGLT2 inhibitors, or DPP-4 inhibitors, though the combination with a DPP-4 inhibitor provides limited additional GLP-1-pathway benefit given the overlapping incretin mechanism. |
| Renal Impairment | No dose adjustment of Duotir is required for mild, moderate, or severe renal impairment based on available pharmacokinetic data. However, dehydration from tirzepatide-related gastrointestinal adverse effects can precipitate acute kidney injury in patients with renal impairment. Monitor renal function and ensure adequate hydration during Duotir initiation and dose escalation in patients with chronic kidney disease. Consult the treating endocrinologist and nephrologist for individualised guidance in patients with significant renal comorbidities. |
| Pregnancy & Lactation | Duotir (Tirzepatide) is not recommended during pregnancy, as tirzepatide may cause fetal harm based on animal reproductive toxicity studies demonstrating adverse embryo-fetal developmental effects at clinically relevant exposures. Females of reproductive potential should use effective contraception during Duotir treatment and for at least 4 weeks after the final dose due to tirzepatide’s prolonged half-life. The use of oral contraceptives may require additional precautions during Duotir initiation and dose escalation due to transient effects on gastric emptying. Breastfeeding is not recommended during Duotir treatment because it is unknown whether tirzepatide is excreted in human milk. Notify the treating endocrinologist immediately if pregnancy occurs during tirzepatide treatment. For patients with type 2 diabetes who become pregnant, transition to a pregnancy-approved antidiabetic regimen in consultation with the treating specialist. |
Who Should Use Duotir (Tirzepatide)?
Duotir (Tirzepatide) is indicated for adults with type 2 diabetes mellitus requiring improved glycaemic control as an adjunct to diet and exercise, and for adults with obesity (BMI 30 kg/m² or above) or overweight (BMI 27 kg/m² or above) with at least one weight-related comorbidity requiring chronic weight management representing two distinct patient populations served by tirzepatide’s dual GIP and GLP-1 receptor agonist mechanism targeting the principal incretin hormone axes that govern postprandial glucose homeostasis, insulin sensitivity, glucagon suppression, gastric emptying, and central appetite regulation.
First, adults with type 2 diabetes mellitus with inadequate glycaemic control on oral antidiabetic monotherapy or combination oral therapy particularly those with HbA1c above 7.5% on metformin, SGLT2 inhibitors, or DPP-4 inhibitors who require injectable incretin-based therapy with the highest available efficacy for HbA1c reduction and concomitant body weight loss represent the primary type 2 diabetes indication population for Duotir. In SURPASS-1 (478 patients, tirzepatide monotherapy vs placebo), tirzepatide 5 mg once weekly achieved HbA1c reduction of 1.87% versus 0.04% placebo (p<0.001) at 40 weeks, with 87% of patients achieving HbA1c below 7.0% versus 20% placebo representing the highest proportion of a study population achieving the standard glycaemic target in any Phase 3 trial of an injectable incretin agent as monotherapy.
Second, adults with type 2 diabetes who have previously used a GLP-1 receptor agonist (semaglutide, liraglutide, dulaglutide) but require greater HbA1c and body weight reduction than GLP-1 agonism alone provides represent a population for whom tirzepatide’s dual GIP/GLP-1 mechanism offers clinically documented incremental efficacy. In SURPASS-2 (1,879 patients), tirzepatide 5 mg achieved HbA1c reduction of 2.01% and body weight reduction of 7.6 kg versus semaglutide 1 mg at 1.86% HbA1c reduction and 5.3 kg body weight loss at 40 weeks (p<0.001 for superiority of tirzepatide 5 mg on HbA1c).
Third, adults with obesity or overweight with at least one weight-related comorbidity including hypertension, dyslipidemia, obstructive sleep apnea, type 2 diabetes, or established cardiovascular disease who require a pharmacological intervention for chronic weight management beyond what lifestyle modification alone achieves represent the chronic weight management indication population for Duotir. In SURMOUNT-1 (2,539 adults with obesity or overweight without type 2 diabetes), tirzepatide 5 mg once weekly achieved 15.0% mean body weight reduction versus 2.4% placebo at 72 weeks (p<0.001), with 42% of patients on 5 mg achieving at least 15% body weight reduction versus 3% placebo.
Fourth, adults with type 2 diabetes and elevated cardiovascular risk who require an agent with both HbA1c-lowering and body weight reduction benefits as part of a comprehensive cardiometabolic risk reduction programme including those who are overweight or obese, hypertensive, or dyslipidaemic alongside their glycaemic management may benefit from tirzepatide’s documented effects on HbA1c, body weight, systolic blood pressure, and lipid parameters across the SURPASS Phase 3 programme. Duotir is contraindicated in patients with personal or family history of MTC or MEN2; is not indicated for type 1 diabetes; requires TB screening to be excluded before initiation; and necessitates dose adjustment of concomitant insulin secretagogues or basal insulin.
Endocrinology centres and diabetes specialist clinics co-sourcing Duotir alongside other systemic diabetes medicines can browse the Mediaid Pharmacy diabetes medicines portfolio for the full selection available for international delivery.
Global Supplier: Mediaid Pharmacy Worldwide Shipping for Duotir (Tirzepatide)
Mediaid Pharmacy is a Dhaka-based supplier of specialty diabetes, endocrinology, and metabolic medicines with worldwide shipping to patients, diabetes specialist centres, endocrinology clinics, obesity medicine programmes, hospital pharmacy departments, and international distributors across all regions. Duotir (Tirzepatide), manufactured by Opsonin Pharma Ltd. in Bangladesh, is supplied as single-dose pre-filled syringes in three dose strengths 2.5 mg/0.5 mL (initiation dose), 5 mg/0.5 mL (first maintenance dose), and 7.5 mg/0.5 mL (escalation maintenance dose) covering the initial titration phase of the approved tirzepatide once-weekly dosing schedule, with pricing quotations, stock confirmation, full product documentation, and end-to-end international delivery tracking for every order.
The single-dose pre-filled syringe format of Duotir supports accurate dose delivery, patient-administered subcutaneous injection convenience, and the structured 4-weekly dose escalation schedule that underpinned tirzepatide’s Phase 3 SURPASS and SURMOUNT trial protocols. Diabetes specialist centres, endocrinology programmes managing type 2 diabetes and obesity, cardiometabolic risk reduction clinics, hospital pharmacy departments co-sourcing GIP/GLP-1 receptor agonist injectable therapies, international distributors, and individual patients can contact the Mediaid Pharmacy team through WhatsApp, phone, or WeChat for all inquiries regarding Duotir Tirzepatide stock availability by strength, current pricing, and international delivery timelines to their country. Procurement teams co-sourcing Duotir with other specialty diabetes or metabolic medicines can browse the complete Mediaid Pharmacy diabetes medicines collection and the Opsonin Pharma medicines portfolio before requesting a consolidated quotation.
Why Choose Duotir (Tirzepatide) from Mediaid Pharmacy?
Duotir (Tirzepatide) delivers the world’s first approved dual GIP and GLP-1 receptor agonist for type 2 diabetes and chronic weight management a first-in-class incretin co-agonist backed by the landmark Phase 3 SURPASS programme (six trials across type 2 diabetes) and SURMOUNT programme (obesity and weight management) that collectively establish tirzepatide as the most efficacious HbA1c-reducing and body weight-reducing injectable incretin agent approved across all comparator-controlled trials. In SURPASS-2 (1,879 patients), tirzepatide 5 mg once weekly achieved HbA1c reduction of 2.01% versus 1.86% semaglutide 1 mg and body weight reduction of 7.6 kg versus 5.3 kg semaglutide 1 mg at 40 weeks the first Phase 3 trial in type 2 diabetes to demonstrate statistically significant superiority of a once-weekly injectable incretin agent over semaglutide 1 mg on both HbA1c and body weight endpoints simultaneously. In SURPASS-1 (478 patients), tirzepatide 5 mg monotherapy achieved HbA1c below 7.0% in 87% versus 20% placebo (p<0.001) and HbA1c below 5.7% (normoglycaemic range) in 32% versus 1% placebo at 40 weeks. In SURMOUNT-1 (2,539 patients with obesity), tirzepatide 5 mg achieved mean body weight reduction of 15.0% versus 2.4% placebo at 72 weeks, with 42% of patients achieving 15% or greater body weight reduction versus 3% placebo.
Tirzepatide’s dual GIP/GLP-1 twincretin mechanism is pharmacologically distinct from selective GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide) and from DPP-4 inhibitors that only prevent endogenous incretin degradation delivering direct, potent, and sustained co-activation of both principal incretin hormone receptors with a single once-weekly subcutaneous injection and a 5-day half-life profile that enables the structured 4-week dose-escalation titration programme to minimise gastrointestinal tolerability burden. The three-strength pre-filled syringe range of Duotir 2.5 mg (initiation), 5 mg (first maintenance), and 7.5 mg (escalation maintenance) precisely covers the first three steps of the approved tirzepatide titration schedule, manufactured by Opsonin Pharma Ltd. in Bangladesh and supplied through Mediaid Pharmacy with worldwide shipping. To source additional Opsonin Pharma diabetes and specialty medicines, visit the Mediaid Pharmacy Opsonin Pharma medicines section and the diabetes medicines portfolio, and contact the team for a personalized quotation.
Frequently Asked Questions About Duotir (Tirzepatide)
What is Duotir (Tirzepatide) used for?
Duotir (Tirzepatide) is the world’s first approved dual GIP and GLP-1 receptor agonist, indicated for two uses: (1) as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus, and (2) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity (BMI 30 kg/m² or above) or overweight (BMI 27 kg/m² or above) with at least one weight-related comorbidity. Duotir (Tirzepatide) simultaneously activates GIP receptors and GLP-1 receptors to stimulate glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, improve insulin sensitivity, and reduce appetite and body weight. The originator brands for tirzepatide are MOUNJARO® (Eli Lilly, FDA-approved May 2022 for type 2 diabetes) and ZEPBOUND® (Eli Lilly, FDA-approved November 2023 for weight management). Duotir, manufactured by Opsonin Pharma Ltd. in Bangladesh, is available through Mediaid Pharmacy with worldwide shipping to patients, diabetes specialist centres, and diabetes and endocrinology clinics.
What is the generic name of Duotir?
The generic name of Duotir is tirzepatide INN. Duotir is the brand name registered by Opsonin Pharma Ltd. for tirzepatide manufactured in Bangladesh. Duotir is formulated as a subcutaneous injection in single-dose pre-filled syringes in three strengths 2.5 mg/0.5 mL, 5 mg/0.5 mL, and 7.5 mg/0.5 mL covering the initiation and first two maintenance steps of the approved once-weekly tirzepatide dose titration schedule. The originator reference brands are MOUNJARO® and ZEPBOUND® (Eli Lilly). Mediaid Pharmacy distributes Duotir globally with worldwide shipping to patients, diabetes centres, endocrinology clinics, obesity medicine programmes, and hospital pharmacy departments.
What is the difference between Duotir (Tirzepatide) and MOUNJARO (Tirzepatide)?
Duotir and MOUNJARO® both contain tirzepatide INN as the active pharmaceutical ingredient and share the same first-in-class dual GIP and GLP-1 receptor agonist mechanism of action for type 2 diabetes and chronic weight management. MOUNJARO® is the originator brand developed and marketed by Eli Lilly, approved by the FDA in May 2022 for type 2 diabetes in adults; ZEPBOUND® (the same molecule) was approved in November 2023 for chronic weight management. Duotir is manufactured by Opsonin Pharma Ltd. in Bangladesh and is supplied in three available strengths 2.5 mg, 5 mg, and 7.5 mg per single-dose pre-filled syringe available through Mediaid Pharmacy for international procurement by specialist diabetes centres and patients in regions where MOUNJARO® may be unavailable or cost-prohibitive. For the full range of diabetes medicines at Mediaid Pharmacy, browse the complete collection.
How is Duotir (Tirzepatide) administered?
Duotir (Tirzepatide) is administered as a subcutaneous injection once weekly in the abdomen, thigh, or upper arm, on the same day each week. The recommended starting dose is 2.5 mg once weekly for 4 weeks, followed by escalation to 5 mg once weekly. If additional glycaemic or weight management efficacy is needed after a minimum of 4 weeks on 5 mg, the dose may be increased to 7.5 mg once weekly. Rotate injection sites each week. Do not inject intravenously or intramuscularly. Do not share pre-filled syringes between patients. If a dose is missed and the next scheduled dose is more than 4 days away, administer Duotir as soon as possible. If the next scheduled dose is within 4 days, skip the missed dose and resume on the regular weekly schedule. Do not administer two doses within 3 days of each other.
What are the side effects of Duotir (Tirzepatide)?
The most commonly reported adverse reactions of tirzepatide in the SURPASS and SURMOUNT Phase 3 trials include nausea, diarrhoea, decreased appetite, vomiting, constipation, dyspepsia, abdominal pain, and injection site reactions. Gastrointestinal adverse events were most frequent during dose initiation and escalation and were generally transient and mild-to-moderate in severity. In SURPASS-2, nausea occurred in 17% of patients on tirzepatide 5 mg versus 18% on semaglutide 1 mg. More serious risks include pancreatitis (discontinue Duotir if suspected), acute kidney injury (due to dehydration from gastrointestinal adverse effects), hypoglycaemia (particularly with concomitant insulin secretagogues or basal insulin), and the boxed warning for thyroid C-cell tumors Duotir is contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or MEN2. Always discuss the complete safety profile, hypoglycaemia risk, thyroid history, pancreatitis history, and concomitant antidiabetic medication adjustment with the treating endocrinologist before and throughout Duotir treatment.
How effective is Tirzepatide (Duotir) for type 2 diabetes and weight loss?
Tirzepatide has demonstrated statistically significant and clinically meaningful efficacy for both type 2 diabetes and chronic weight management across six SURPASS Phase 3 trials and four SURMOUNT Phase 3 trials. For type 2 diabetes: SURPASS-1 showed tirzepatide 5 mg achieved HbA1c reduction of 1.87% versus 0.04% placebo, with 87% of patients achieving HbA1c below 7.0% versus 20% placebo at 40 weeks. SURPASS-2 showed tirzepatide 5 mg achieved HbA1c reduction of 2.01% versus 1.86% semaglutide 1 mg (p<0.001) and body weight loss of 7.6 kg versus 5.3 kg at 40 weeks. For weight management: SURMOUNT-1 showed tirzepatide 5 mg achieved 15.0% mean body weight reduction versus 2.4% placebo at 72 weeks, with 42% of patients achieving 15% or greater weight loss versus 3% placebo. Duotir delivers the same active ingredient tirzepatide INN at the approved subcutaneous once-weekly doses, sourced through Mediaid Pharmacy with worldwide shipping. For the complete diabetes medicines range at Mediaid Pharmacy, browse the full portfolio for international delivery.
Is Duotir (Tirzepatide) safe during pregnancy or while breastfeeding?
Duotir (Tirzepatide) is not recommended during pregnancy, as tirzepatide may cause fetal harm based on animal reproductive toxicity studies. Females of reproductive potential must use effective contraception during Duotir treatment and for at least 4 weeks after the final dose, given tirzepatide’s approximately 5-day plasma half-life. Patients using oral contraceptives should consider a backup or alternative contraception method during the first 4 weeks after Duotir initiation or dose escalation, as tirzepatide’s transient effect on gastric emptying may reduce oral contraceptive absorption during this window. Breastfeeding is not recommended during Duotir treatment. If pregnancy occurs during tirzepatide treatment, notify the treating endocrinologist immediately. Consult the treating specialist and review the current prescribing information for the most up-to-date reproductive and lactation safety guidance.
Can I order Duotir (Tirzepatide) online with worldwide shipping?
Yes. Mediaid Pharmacy supplies Duotir (Tirzepatide) in 2.5 mg, 5 mg, and 7.5 mg pre-filled syringe strengths to patients, diabetes specialist centres, endocrinology clinics, obesity medicine programmes, hospital pharmacy departments, and healthcare providers globally. Contact Mediaid Pharmacy via WhatsApp, phone, or WeChat at +8801773428128, or email info@mediaidpharmacy.com for pricing by strength, current stock availability, and international delivery details for your country.
Order Duotir (Tirzepatide) with Worldwide Shipping
Phone / WhatsApp / WeChat: +8801773428128 | Email: info@mediaidpharmacy.com




Reviews
There are no reviews yet.